Search Results - "FIORI, GINEVRA"

Refine Results
  1. 1

    Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases by Bruni, Cosimo, Bitti, Roberta, Nacci, Francesca, Cometi, Laura, Tofani, Lorenzo, Bartoli, Francesca, Fiori, Ginevra, Matucci-Cerinic, Marco

    Published in Clinical rheumatology (2021)
    “…Objective SB5 showed comparable efficacy and safety profile in respect to adalimumab originator (ADA) in randomized clinical trials of rheumatoid arthritis…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases by Bruni, Cosimo, Cigolini, Cosimo, Tesei, Giulia, Cometi, Laura, Bartoli, Francesca, Fiori, Ginevra, Nacci, Francesca, Bellando-Randone, Silvia, Guiducci, Serena, Matucci-Cerinic, Marco

    Published in European journal of rheumatology (01-10-2021)
    “…Osteoporosis (OP) can complicate the course of rheumatic musculoskeletal diseases (RMDs) and connective tissue diseases (CTDs). Denosumab, a monoclonal…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10

    Transitional connective tissue diseases: description of four cases by Susanna, Cappelli, Philippe, Guilpain, Silvia, Bellando-Randone, Ginevra, Fiori, Francesca, Bartoli, Jelena, Blagojevic, Francesca, Nacci, Letizia, Conforti Maria, Francesca, Braschi, Loic, Guillevin, Marco, Matucci-Cerinic

    Published in Current rheumatology reviews (01-01-2014)
    “…The term overlap syndromes (OS) is used to define a group of disorders characterized by the presence, in the same patient, of clinical features typical for…”
    Get more information
    Journal Article
  11. 11

    Persistence of remission after lengthening of golimumab in inflammatory joint diseases by Damiani, Arianna, Bartoli, Francesca, Pacini, Giovanni, Carboni, Davide, Bellando Randone, Silvia, Fiori, Ginevra, Matucci-Cerinic, Marco, Guiducci, Serena

    Published in Clinical and experimental rheumatology (01-05-2023)
    “…In refractory inflammatory joint diseases (IJDs) biological disease-modifying anti-rheumatic drugs (bDMARDs) may achieve remission. EULAR recommends bDMARD…”
    Get more information
    Journal Article
  12. 12
  13. 13

    Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis by Bruni, Cosimo, Guiducci, Serena, Bellando-Randone, Silvia, Lepri, Gemma, Braschi, Francesca, Fiori, Ginevra, Bartoli, Francesca, Peruzzi, Francesca, Blagojevic, Jelena, Matucci-Cerinic, Marco

    Published in Rheumatology (Oxford, England) (01-01-2015)
    “…The aim of this study was to evaluate the presence of digital lesions in very early diagnosis of SSc (VEDOSS) patients and its possible association with…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    Premedication prevents infusion reactions and improves retention rate during infliximab treatment by Bartoli, Francesca, Bruni, Cosimo, Cometi, Laura, Blagojevic, Jelena, Fiori, Ginevra, Tofani, Lorenzo, Galluccio, Felice, Furst, Daniel E., Matucci Cerinic, Marco

    Published in Clinical rheumatology (01-11-2016)
    “…Infliximab (IFX) is an anti-tumor necrosis factor-alpha antibody used to treat inflammatory joint diseases. Infusion reactions (IR) can occur during and after…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study by Colaci, Michele, Lumetti, Federica, Giuggioli, Dilia, Guiducci, Serena, Bellando-Randone, Silvia, Fiori, Ginevra, Matucci-Cerinic, Marco, Ferri, Clodoveo

    Published in Clinical and experimental rheumatology (01-09-2017)
    “…Raynaud's phenomenon and chronic/recurrent digital ulcers (DU) are main features of systemic sclerosis (SSc). Their treatment includes both systemic (i.e.,…”
    Get full text
    Journal Article